Sinopharm Group Co., Ltd.

Pharmaceuticals
China
Executive 1Wei Yulin, President; | President;
Executive 2Mr. Guangpu Li, Vice President; | Executive Vice President;
Earnings Per Share Growth (%)24.72%
Cost of Goods Sold (US$ Millions)$29,615
Current Liabilities (US$ Millions)$13,860
Total Assets (US$ Millions)$17,768
Long Term Debt (Millions)$680
Return on Equity20.86%
Revenue (US$ Millions)$32,288
Total Company Assets$20,730
Revenue Growth (%)19.87%
Net Income (US$ Millions)$733
Earnings Per Share (US$)$0.18
Total Equity (US$ Millions)$4,412
Profit Margin (%)2.27%
Debt To Equity Ratio (%)0.15%
Inventories (Millions)$3,272